Anti-tumor activity of the beta-adrenergic receptor antagonist propranolol in neuroblastoma

Neuroblastoma (NB) is a pediatric tumor of the sympathetic nervous system, which is often associated with elevated catecholamines. More than half of patients with metastatic NB relapse and survival is extremely poor with current therapies. In a high-throughput screen of FDA-approved drugs we identif...

Full description

Bibliographic Details
Main Authors:	Wolter, Jennifer K, Wolter, Nikolaus E, Blanch, Alvaro, Partridge, Teresa, Cheng, Lynn, Morgenstern, Daniel A., Podkowa, Monika, Kaplan, David R., Irwin, Meredith S.
Format:	Online
Language:	English
Published:	Impact Journals LLC 2013
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3960198/

id	pubmed-3960198
recordtype	oai_dc
spelling	pubmed-39601982014-04-04 Anti-tumor activity of the beta-adrenergic receptor antagonist propranolol in neuroblastoma Wolter, Jennifer K Wolter, Nikolaus E Blanch, Alvaro Partridge, Teresa Cheng, Lynn Morgenstern, Daniel A. Podkowa, Monika Kaplan, David R. Irwin, Meredith S. Research Paper Neuroblastoma (NB) is a pediatric tumor of the sympathetic nervous system, which is often associated with elevated catecholamines. More than half of patients with metastatic NB relapse and survival is extremely poor with current therapies. In a high-throughput screen of FDA-approved drugs we identified anti-NB activity for the nonselective β-adrenergic receptor antagonist propranolol hydrochloride. Impact Journals LLC 2013-11-04 /pmc/articles/PMC3960198/ /pubmed/24389287 Text en Copyright: © 2014 Wolter et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Wolter, Jennifer K Wolter, Nikolaus E Blanch, Alvaro Partridge, Teresa Cheng, Lynn Morgenstern, Daniel A. Podkowa, Monika Kaplan, David R. Irwin, Meredith S.
spellingShingle	Wolter, Jennifer K Wolter, Nikolaus E Blanch, Alvaro Partridge, Teresa Cheng, Lynn Morgenstern, Daniel A. Podkowa, Monika Kaplan, David R. Irwin, Meredith S. Anti-tumor activity of the beta-adrenergic receptor antagonist propranolol in neuroblastoma
author_facet	Wolter, Jennifer K Wolter, Nikolaus E Blanch, Alvaro Partridge, Teresa Cheng, Lynn Morgenstern, Daniel A. Podkowa, Monika Kaplan, David R. Irwin, Meredith S.
author_sort	Wolter, Jennifer K
title	Anti-tumor activity of the beta-adrenergic receptor antagonist propranolol in neuroblastoma
title_short	Anti-tumor activity of the beta-adrenergic receptor antagonist propranolol in neuroblastoma
title_full	Anti-tumor activity of the beta-adrenergic receptor antagonist propranolol in neuroblastoma
title_fullStr	Anti-tumor activity of the beta-adrenergic receptor antagonist propranolol in neuroblastoma
title_full_unstemmed	Anti-tumor activity of the beta-adrenergic receptor antagonist propranolol in neuroblastoma
title_sort	anti-tumor activity of the beta-adrenergic receptor antagonist propranolol in neuroblastoma
description	Neuroblastoma (NB) is a pediatric tumor of the sympathetic nervous system, which is often associated with elevated catecholamines. More than half of patients with metastatic NB relapse and survival is extremely poor with current therapies. In a high-throughput screen of FDA-approved drugs we identified anti-NB activity for the nonselective β-adrenergic receptor antagonist propranolol hydrochloride.
publisher	Impact Journals LLC
publishDate	2013
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3960198/
_version_	1612069615929655296

Anti-tumor activity of the beta-adrenergic receptor antagonist propranolol in neuroblastoma

Similar Items